🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the effort against increasingly resistant strains of the infection, according to health experts.

A Global Health Concern

Cases of gonorrhoea are on the rise globally, with data suggesting in excess of 82 million infections annually. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the face of growing infection rates, escalating drug resistance and the highly restricted therapeutic options at this time.”

Health officials are deeply concerned about the surge in drug-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Receive Approval

Zoliflodacin, marketed under the name a brand name, was approved by the American regulatory agency in December for use against gonorrhoea. This STI can lead to major issues, including infertility. Researchers anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This treatment, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a unique collaborative effort for drug creation. The charitable organization GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Data and Global Access

As per results published in a prominent scientific publication, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The research included over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to make available and distribute the drug in numerous regions with limited resources.

Clinicians treating patients have voiced optimism. Having a easy-to-administer therapy like this is seen as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.